StockOptionsView vs Biotech Pulse

Name: StockOptionsView Subtitle: Stock & Options Chain Analysis StockOptionsView gives investors a clean, powerful way to analyze stocks, earnings expectations, and options strategies all in one place. Whether you're preparing for an earnings report, evaluating analyst sentiment, or building different options strategies, this app delivers the insights you need with simplicity and speed. Explore detailed fundamentals, price targets, volatility trends, and full options chains for 500+ publicly traded companies. StockOptionsView is designed for traders who want fast data, and straightforward tools that make complex decisions easier. Key Features Earnings & Analyst Insights View the company's stock price See analyst price targets: average, high, and low Understand market sentiment with analyst recommendations: Strong Buy, Buy, Hold, Sell, Strong Sell Track valuation metrics including P/E ratio, Forward P/E, Market Cap, Dividend Yield, and Beta Quickly reference 52-week high and low levels Price History & Volatility Analyze 6 month price performance Review historical volatility to understand risk and movement Identify trends leading into earnings or major events Full Options Chain Access call and put options for every supported company View strike prices and implied volatility Compare options to build informed strategies Options Strategy Builder Create and visualize custom strategies Simulate profit and loss outcomes based on your market expectations Instantly see how price, volatility, and time affect your position Unusual Activity Detection High volume detection and top unusual calls and puts Coverage of 500+ Companies Tech giants, consumer brands, healthcare, finance and even more. StockOptionsView includes a wide range of companies so you can research and trade with confidence.Why Traders and Investors Love StockOptionsView Clean, simple interface, Perfect for earnings season, and everything you need in one app. Whether you're preparing for a big earnings play or refining your options strategy, StockOptionsView helps you make smarter, more confident decisions. DISCLAIMER: Prices displayed are similar to real market values and based on actual market data, but are not always accurate and should not be relied upon as current. This app is intended for users who understand how stock markets and options trading work. Always verify data independently before making any investment decisions. This app does not provide financial advice.

The biotech catalyst tracker for serious investors. Real-time FDA approvals, PDUFA dates, EMA and CHMP committee opinions, SEC filings, clinical trial readouts, and primary-source company news — pushed the moment they hit the regulatory record. WHO IT'S FOR Biotech investors, pharma analysts, healthcare hedge funds, and retail traders who need to see what just happened on a name BEFORE the wire-service summary hits Twitter. FREE FEATURES (no account, no signup) • Real-time FDA approval, PDUFA, CRL, and Warning Letter alerts • EU EMA marketing authorisation feed (UK + EEA centralised approvals) • SEC 8-K filings, press releases, and clinical trial updates • Forward catalyst calendar with PDUFA, AdCom, and CHMP dates • Push notifications when a watchlisted ticker has an event • Watchlist + per-ticker News, Pipeline, Drugs, Intelligence tabs • Indication / drug-class search ("multiple sclerosis", "GLP-1", "CAR-T") • Drug detail with FAERS adverse-event severity and primary-source link to Drugs@FDA • Watchlist Compare view — side-by-side pipeline depth + next catalyst BIOTECH PULSE PRO ($9.99/mo or $79.99/yr, with 7-day free trial) Twelve institutional-grade Pro features, every one sourced from a primary regulatory or scientific feed: • Insider buys — SEC Form 4 executive open-market purchases, 10b5-1 plans filtered out • 13F institutional holdings — quarterly changes, biotech-whale callouts (Baker Bros, BVF, RA Capital, Perceptive) • 8-K dilution radar — automatic offering / shelf / ATM classification • 8-K Item 8.01 content classifier — CRL, PDUFA, AdCom, trial readout, partnership, regulatory filing categories • Material agreements — 8-K Item 1.01 partnership / licensing / supply detection • AdCom calendar — Federal Register FDA Advisory Committee meetings + briefing-doc URLs • Orange Book + USPTO patent timelines — every unexpired patent with USPTO Patent Term Adjustment chips (PTA extends patent expiry past the Orange Book listing — the most under-priced biotech signal), Re-exam warning flags, family-size hints, and one-tap to the patent document on Google Patents • FDA Warning Letter history • FDA device clearances — 510(k) and PMA by manufacturer • DailyMed label history — every SPL version bump (indication, black-box, REMS) • CMS Open Payments — KOL payment network per sponsor • CMS Part D utilization — 5 years of Medicare prescription volume • Drug shortages — FDA-tracked active shortages with push alerts on status changes • Conference abstracts — ASH, ASCO, AHA, AAN, DDW • Custom alert rules — unlimited, all 4 trigger types including 8-K Item filtering 100% PRIMARY-SOURCE DATA SEC EDGAR. openFDA. EMA. CHMP. Health Canada. CMS. NIH. Federal Register. ClinicalTrials.gov. DailyMed. USPTO. ash.confex.com. No Bloomberg, no Refinitiv, no FactSet, no paid data vendors. No AI hallucinations. No analyst recommendations. Just the data. NO TRACKING No analytics SDK. No advertising SDK. No cross-app tracking. No account required. External article links open in Safari's isolated process. We don't know who you are. Pro auto-renews unless cancelled at least 24 hours before the end of the current period. Cancel anytime in iOS Settings → Apple ID → Subscriptions. Terms of Use: https://bioturd.com/terms Privacy Policy: https://bioturd.com/privacy